Opioid Crisis Accountability Act of 2018
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in senate (Apr 17, 2018)
Opioid Crisis Accountability Act of 2018
This bill amends the Federal Food, Drug, and Cosmetic Act to prohibit a drug manufacturer from engaging in illegal marketing and distribution practices, including falsely advertising, promoting, or marketing that an opioid has no addiction-forming or addiction-sustaining qualities or risks.
The bill penalizes drug manufacturers or distributors who illegally advertise, market or distribute an opioid product, including by (1) imposing a civil fine or salary confiscation, (2)revoking any remaining period of market exclusivity for such product, (3)requiring reimbursement of federal funding received for such product, and (4)prohibiting certain tax credits.
What just happenedApr 17, 2018
Read twice and referred to the Committee on Finance.
Who’s behind it
- Introduced in SenateApr 17, 2018
- Apr 17, 2018IntroReferral
Read twice and referred to the Committee on Finance.
Finance Committee - Apr 17, 2018IntroReferral10000
Introduced in Senate